Spatial PTEN SMAD4 Expression Analysis for Adenoma-Adenocarcinoma Transition Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to accurately identify cancer stem cell-like zones and adenoma-adenocarcinoma transition zones in colorectal cancer, which are crucial for diagnosing invasive potential and treatment response, due to genetic heterogeneity and complex morphological transitions.
Innovation Solution
The method involves assaying colonic tumor samples for PTEN expression and detecting alternating spatial patterns of PTEN, SMAD4, TP53, CD44, ALDH1, and EZH2, among others, using immunohistochemistry, to identify cancer stem cells and transition zones, and determining genomic losses such as 10q/PTEN and 18q/SMAD4 genomic losses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional morphological assessment methods are used to distinguish adenoma from adenocarcinoma, then diagnostic simplicity is maintained, but measurement precision and reliability are insufficient due to genetic heterogeneity and complex morphological transitions
Solution Approach 1:
The patent segments the diagnostic process into multiple independent assessment dimensions: morphological evaluation, PTEN expression analysis, SMAD4 expression analysis, and genomic loss detection. Each dimension provides specific information about tumor characteristics, and together they form a comprehensive diagnostic framework that overcomes the limitations of single-method assessment
Solution Approach 2:
The patent introduces new diagnostic parameters (PTEN expression levels, SMAD4 expression levels, genomic loss patterns) to complement traditional morphological parameters. By measuring multiple parameters simultaneously, the diagnostic system achieves higher precision in distinguishing adenoma from adenocarcinoma and identifying cancer stem cell-like zones
2Measurement precision
If multiple genetic markers are assayed to identify cancer stem cells and transition zones, then measurement precision improves, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent employs immunohistochemistry as a universal detection method that can simultaneously assess multiple genetic markers (PTEN, SMAD4, and others) within the same tissue section. This multi-functional approach allows comprehensive molecular characterization without requiring separate complex assays for each marker, thereby reducing overall detection difficulty while maintaining high identification accuracy
3Reliability
If genomic loss analysis is performed to determine 10q/PTEN and 18q/SMAD4 losses, then reliability of invasive potential prediction improves, but loss of time in diagnostic process increases
Solution Approach 1:
The patent performs genomic loss analysis on tissue samples obtained during routine diagnostic procedures, utilizing material that would otherwise be discarded or used for basic morphology. By conducting molecular analyses on existing samples rather than requiring additional biopsies or time-intensive culturing, the method achieves reliable prediction of invasive potential without significant additional time loss
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of high-grade adenomas, early adenocarcinomas, and cancer stem cells, predicting invasive transformation and treatment responses to NF-kB and TGF-beta pathway targeted therapies, thereby improving diagnostic accuracy and treatment planning.
Implementation Method 1
assaying colonic tumor samples for PTEN expression and detecting alternating spatial patterns of PTEN, SMAD4, TP53, CD44, ALDH1, and EZH2, among others, using immunohistochemistry
Data Source
AI summary
Methods and kits for detecting alternating spatial expression of PTEN and, optionally, SMAD4, CD44, and/or TP53 in colonic tumors are described. The methods and kits are useful for identifying a cancer stem cell (CSC)-like zone within a colonic tumor, identifying an adenoma-adenocarcinoma (Ad-ACA) transition zone in a colorectal cancer (CRC) tumor, identifying a CRC tumor that contains high-grade adenoma and/or early adenocarcinoma regions, identifying CSCs in a CRC tumor, diagnosing a subject with high-grade colon adenoma and/or early adenocarcinoma, and determining the likelihood that a colonic tumor in a subject will undergo invasive transformation if left untreated.